%0 Journal Article %A N. DITSCH %A A. VODERMAIER %A A. HINKE %A S. BURGHARDT %A M. LENHARD %A B. LĂ–HRS %A B. TOTH %A F. VON KOCH %A S. KAHLERT %A I. BAUERFEIND %A G. E. KONECNY %A S. LOIBL %A G. VON MINCKWITZ %A M. UNTCH %T Dose-dense Intensified Sequential Versus Conventionally-dosed Anthracycline and Taxane-containing Neoadjuvant Therapy in Patients with Inflammatory Breast Cancer %D 2012 %J Anticancer Research %P 3539-3545 %V 32 %N 8 %X Background: This post-hoc analysis aimed to compare an intense dose-dense sequential chemotherapy (DD-CT) and a conventionally-dosed chemotherapy (CD-CT) in the neoadjuvant AGO-1 study, focusing on the subgroup with inflammatory breast cancer (IBC). Patients and Methods: Out of 668 randomised patients, 101 patients presented with IBC. Patients received epirubicin followed by paclitaxel every 2 weeks (DD-CT) or simultaneously every 3 weeks (CD-CT). Results: No differences in pathological complete response rates were observed [odds ratio (OR)=1.27, p=0.33]. Most patients were scheduled for mastectomy before starting therapy; however, in 21.7% breast-conserving surgery was performed. Disease-free survival rates [Hazard Ratio (HR)=0.65; p=0.597] and overall survival rates (HR=1.40; p=0.327) were similar for both treatment arms. Patients with breast-conserving surgery had a significantly better outcome than patients treated with mastectomy (disease-free survival: HR=0.41; p=0.034 and overall survival: HR=0.09; p=0.003). Conclusion: Patients with IBC benefited not from DD-CT but from breast-conserving surgery after neoadjuvant chemotherapy. %U https://ar.iiarjournals.org/content/anticanres/32/8/3539.full.pdf